ERBA Diagnostics Mannheim acquires Lumora

Cambridgeshire, UK, 7 September 2015 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial markets, has been acquired by ERBA Diagnostics Mannheim, a leading global player in the in-vitro diagnostics market.

The acquisition will see Lumora’s molecular diagnostics technology for the clinical and industrial sectors merged with ERBA Diagnostics Mannheim’s existing businesses for in-vitro diagnostic testing across the world, covering a wide range of market segments. Financial details were not disclosed.

Lumora’s technology provides a strong addition to the ERBA Diagnostics Mannheim portfolio. Through the acquisition of the Lumora technology, ERBA Mannheim has been able to expand its portfolio to include molecular testing for hospital acquired infections and emerging market specific infectious diseases, such as HIV and respiratory diseases. Alongside the molecular testing, ERBA Diagnostics Mannheim will be able to further commercialise Lumora’s technologies such as RapidMag and BART. In addition, Lumora, has a number of ongoing commercial partnerships which will continue following the acquisition.

Mr. Suresh Vazirani, Chairman and Managing Director of ERBA Diagnostics Mannheim, said: “We are very pleased to have concluded this acquisition. Lumora has a strong portfolio of molecular technologies in growing areas which will complement our existing business. In addition, Lumora’s excellent commercial partnerships can be used to further expand ERBA Diagnostic Mannheim’ global business.”

Laurence Tisi, CEO of Lumora, said: “ERBA Diagnostics Mannheim is an excellent home for Lumora’s technology. The company has a strong global presence and is well established in a number of key market segments. With the acquisition of Lumora, and its novel technology, ERBA Diagnostics Mannheim is now well placed to expand the utility of the technologies globally.

Hayden Jeffreys, Commercial Director at Lumora, said: “The successful conclusion of the acquisition by ERBA Diagnostics Mannheim shows the strength of Lumora’s technology. Not only is it ideal for specific markets such as hospital acquired infections and HIV testing, the technologies can also be applied to a wide range of existing clinical and industrial diagnostics.”


For further information please contact:
Tony Stephenson, Director
Exitus Communications
Tel: +44 (0)7899 796655
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Notes to Editors:

About Lumora
Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora's easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is active in commercialising its technology and our development and commercialisation partners include international biotechnology, clinical diagnostic and industrial microbiology companies. Lumora's corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.

About ERBA Diagnostics Mannheim
ERBA Diagnostics Mannheim is a fully integrated global in vitro diagnostics company, offering a comprehensive suite of clinical testing products to the growing number of smaller hospitals, reference labs, and physician clinics in the developed and emerging markets with reliable, affordable and innovative health care products. ERBA Mannheim develops, manufactures, and markets a range of automated instruments, test kits, and reagents for clinical chemistry, microbiology, haematology, diabetes, immunology, urine chemistry, critical care and hemostasis testing. The company based in Mannheim, Germany serves more than 25,000 customers spread across 100+ countries through its 1500+ committed employees and an extensive distributor network. For more information, please